The Trump administration is backing a roughly $200 million public-private partnership for a cancer vaccine through the National Cancer Institute, the Wall Street Journal first reported. It will fund clinical trials of vaccines that activate the immune system to attack tumors.
The various types of vaccines covered by the funding include those based on messenger RNA, a classification that saw its programs terminated under Kennedy last year.
Market Data 
Markets 
AI
